JP2024532325A5 - - Google Patents
Info
- Publication number
- JP2024532325A5 JP2024532325A5 JP2024512986A JP2024512986A JP2024532325A5 JP 2024532325 A5 JP2024532325 A5 JP 2024532325A5 JP 2024512986 A JP2024512986 A JP 2024512986A JP 2024512986 A JP2024512986 A JP 2024512986A JP 2024532325 A5 JP2024532325 A5 JP 2024532325A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- tead
- acceptable salt
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163239506P | 2021-09-01 | 2021-09-01 | |
| US63/239,506 | 2021-09-01 | ||
| PCT/IB2022/058130 WO2023031798A1 (en) | 2021-09-01 | 2022-08-30 | Dosing regimen for a tead inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024532325A JP2024532325A (ja) | 2024-09-05 |
| JP2024532325A5 true JP2024532325A5 (https=) | 2025-09-08 |
Family
ID=83355146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024512986A Pending JP2024532325A (ja) | 2021-09-01 | 2022-08-30 | Ｔｅａｄ阻害剤の投薬レジメン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240358720A1 (https=) |
| EP (1) | EP4395768A1 (https=) |
| JP (1) | JP2024532325A (https=) |
| KR (1) | KR20240055021A (https=) |
| CN (1) | CN117835977A (https=) |
| AU (1) | AU2022340987A1 (https=) |
| CA (1) | CA3225444A1 (https=) |
| IL (1) | IL309246A (https=) |
| MX (1) | MX2024002566A (https=) |
| TW (1) | TW202327579A (https=) |
| WO (1) | WO2023031798A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119968359A (zh) | 2022-09-29 | 2025-05-09 | 英矽智能科技知识产权有限公司 | Tead抑制剂及其使用方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3156404A1 (en) * | 2015-10-15 | 2017-04-19 | Inventiva | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma |
| CA3142351A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| EP4030233B1 (en) | 2019-09-18 | 2025-05-07 | Ningbo Sunny Opotech Co., Ltd. | Periscopic camera module and electronic device |
| UY39129A (es) | 2020-03-16 | 2021-10-29 | Novartis Ag | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead |
| CA3205726A1 (en) | 2021-01-25 | 2022-07-28 | Alfredo C. Castro | Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer |
-
2022
- 2022-08-30 US US18/687,599 patent/US20240358720A1/en active Pending
- 2022-08-30 IL IL309246A patent/IL309246A/en unknown
- 2022-08-30 WO PCT/IB2022/058130 patent/WO2023031798A1/en not_active Ceased
- 2022-08-30 CN CN202280057415.5A patent/CN117835977A/zh active Pending
- 2022-08-30 MX MX2024002566A patent/MX2024002566A/es unknown
- 2022-08-30 CA CA3225444A patent/CA3225444A1/en active Pending
- 2022-08-30 EP EP22772596.7A patent/EP4395768A1/en active Pending
- 2022-08-30 KR KR1020247009905A patent/KR20240055021A/ko active Pending
- 2022-08-30 JP JP2024512986A patent/JP2024532325A/ja active Pending
- 2022-08-30 AU AU2022340987A patent/AU2022340987A1/en active Pending
- 2022-09-01 TW TW111133168A patent/TW202327579A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021120406A5 (ja) | 癌を治療するための組み合わせ物 | |
| JP2024532374A5 (https=) | ||
| Zhen et al. | The efficacy and safety of apatinib treatment for patients with unresectable or relapsed liver cancer: a retrospective study | |
| RU2014128513A (ru) | Раковый маркер и терапевтическая мишень | |
| JP2010043114A (ja) | 腫瘍転移および癌の治療 | |
| CN104436194A (zh) | 具有协同增效作用的抗癌组合物 | |
| JP2024539852A5 (https=) | ||
| JP2020531463A5 (https=) | ||
| JP2022523045A5 (https=) | ||
| JP2024546605A5 (https=) | ||
| JP2024532325A5 (https=) | ||
| Kim et al. | A single-arm, prospective, phase II study of cisplatin plus weekly docetaxel as first-line therapy in patients with metastatic or recurrent salivary gland cancer | |
| CN111558044A (zh) | 一种包含舒尼替尼的药物组合物及其制剂和应用 | |
| JP2024125139A5 (https=) | ||
| JP2023156372A5 (https=) | ||
| Wesolowski et al. | Use of chemotherapy for patients with bone and soft-tissue sarcomas | |
| JP2021511344A5 (https=) | ||
| Monk et al. | Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) | |
| JP2024535053A5 (https=) | ||
| Satake et al. | Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane | |
| JP2022508066A (ja) | 化学療法とリコンビナントｓ． ｒｏｌｆｓｉｉレクチンとの併用 | |
| AU2003241024A1 (en) | Methods and compositions for radioimmunotherapy of brain and cns tumors | |
| AU2004292933B2 (en) | Targeting of Erb antigens | |
| AU2020278733B2 (en) | Quinoline derivatives for treatment of head and neck cancer | |
| JP2023517671A5 (https=) |